About Brigid Bio
A spin-out from the University of Aberdeen, Brigid Bio is developing first-in class monoclonal antibody-based therapies for life-threatening and drug resistant invasive fungal infections.
Our novel antifungal biologics have a new mechanism of action, serving an area of high unmet medical need. Mortality associated with invasive fungal infections are up to 80% in immunocompromised patients including oncology, transplantation and abdominal surgeries.
Our innovative drug discovery platform combines proteomics and transcriptome profile techniques to identify key fungal cell wall markers critical in infection and drug resistance. Using phage display technology and guided epitope selection strategies, we have generated fully human monoclonal antibodies to unique drug targets with superior therapeutic efficacy in an invasive candidiasis model comparable to the fungicidal drug caspofungin.
Watch our video below for further information.
Key Features
Novel Drugs Targets
Relevant in infection & drug resistance
First in class human mAbs
Superior efficacy in infection model
Increased biological half-life
Once a month dosing
Pan Candida
C. albicans, C. auris, C. glabratta, C. tropicalis
Improved Safety & Efficacy
Address DDIs and drug resistance
Our Team
Chris Jones
Executive Chairman
Dr Soumya Palliyil
Co-Founder & CEO
Prof Carol Munro
Co-Founder & CSO
Prof Andy Porter
Co-Founder & Non Exec-Director
Dr Dan Ozanne
CMC Advisor
David Armour
Financial Advisor
Prof Mahamoud Ghannoum
Therapeutics Development Advisor
Get In Touch
If you would like further information about our solution please get in contact with us.
We would love to hear from Oncologists, Infectious Disease Consultants, as well as those involved in R&D within the Biotech and Pharma industries.